ERBB2 and breast carcinoma: Due to the molecular heterogeneity of breast cancer and various resulting therapeutic regimes, a multitude of tissue and serum biomarkers have been established for breast cancer management, like the tissue expression of the progesterone receptor (PR), the estrogen receptor (ER), the human epidermal growth factor receptor (HER2) and Ki-67 [5].